Intraperitoneal cisplatin - mitoxantrone in ovarian cancer patients with minimal residual disease


TOPUZ E., AYDINER A., SAIP P. M., BENGISU E., BERKMAN S., Disci R.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.18, no.1, pp.71-75, 1997 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 1
  • Publication Date: 1997
  • Journal Name: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.71-75
  • Istanbul University Affiliated: Yes

Abstract

A phase II trial was conducted to further explore the potential of salvage intraperitoneal (IP) cisplatin-based therapy in patients with residual ovarian cancer. Twenty-five patients were treated with a regimen of cisplatin (75 mg/m(2)) and mitoxantrone (15 mg/m(2)) delivered IP every three weeks for a maximum of six cycles. Ten patients achieved a pathologically complete response (pCR) and six were clinically stable without evidence of disease. After a median follow-up of 18 months, the median progression-free survival (PFS) was 16 months (95% confidence interval - CI - 3-29%). The actuarial PFS at 24 months was 36% (95% CI 13-59). Overall eight out of 25 patients (32%) had an IP relapse and thus were considered as local treatment failures, The major toxic side effects were nausea, vomiting abdominal pain and renal toxicity. Future trials exploring IP delivery nf these drugs should attempt rn optimite drug dose and schedule and subset analysis of clinical studies should help in identifying patients who are particularly sensitive to this therapeutic approach.